Premium
Antibody‐guided diagnosis and therapy of malignant lesions
Author(s) -
Kalofonos H. P.,
Stewart S.,
Epenetos A. A.
Publication year - 1988
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910410718
Subject(s) - medicine , ovarian cancer , monoclonal antibody , cancer , metastatic breast cancer , antibody , breast cancer , lung cancer , scintigraphy , pathology , metastasis , oncology , immunology
Tumour associated monoclonal antibodies (MAbs) HMFGI, HMFG2 and HI7E2, labelled with 123 iodine or III indium, were used to detect primary and metastatic cancer by external body scintigraphy in patients with ovarian, breast and non‐small cell lung cancer (NSCC). Successful localisation was seen in all patients with primary and 80% of the metastatic NSCC, 50% of primary and 70% of metastatic breast cancer lesions and in 80% of patients with metastatic ovarian cancer. On the other hand, imaging carried with a radiolabelled non‐specific MAb produced positive results in 3 out of 5 cases with primary NSCC. Therefore, non‐specific imaging should be further studied in clinical research for the evaluation of the specificity of radioimmunodetection. A therapeutic procedure which has shown promise is that of intracavity administration of radiolabelled antibodies. Twenty‐nine patients with resistant ovarian cancer have been treated with intraperitoneal 131 l‐labelled MAbs (HMFGI, HMFG2, AUAI, HI7E2). There were no significant responses in 8 patients with gross disease. There were 2 responses in 15 assessable patients with tumour nodules of >2 cm in diameter. Out of 6 patients with microscopic disease, 4 are disease‐free with follow‐up time of 6‐40 months (mean =17.5 months).